Novasep has in the past two years made several key moves that have resulted in substantial successes.
They include the:
– Announcement of strategic investments with one of the largest chromatography plant in the world to produce pharmaceutical Omega-3 (completed end 2014) and an antibody-drug conjugate production plant (to be completed in 2016),
– Sales process reorganization to favor the acquisition of strategic projects,
– Development of the biopharma CMO in the immunotherapy and vaccines business,
– Large-scale project wins confirming the success of the Complete Process Line strategy in industrial biotech, and
– Divestment of the Pharmachem plant, significantly de-risking the business.
These changes have led to 7% sales growth to €266 million (US$291.89 million) in 2015 and 3% increase in EBITDA margin rate (8.5% to 11.5%).
For the current year 2016, with its robust backlog, Novasep anticipates further revenue growth in Synthesis, a continuation of the strong revenue level achieved by Biopharma in 2015 and a rebound of Industrial Biotech revenue to historic levels.
